<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03340844</url>
  </required_header>
  <id_info>
    <org_study_id>CETUPANC</org_study_id>
    <nct_id>NCT03340844</nct_id>
  </id_info>
  <brief_title>Role of CTC´s Spread During Pancreaticoduodenectomy in Patients With Pancreatic and Periampullary Tumors</brief_title>
  <acronym>CETUPANC</acronym>
  <official_title>Role of Circulating Tumor Cells (CTC´s) Spread During Pancreaticoduodenectomy in Metastasis and Survival Rates in Patients With Pancreatic and Periampullary Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación Pública Andaluza para la gestión de la Investigación en Sevilla</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundación Pública Andaluza para la gestión de la Investigación en Sevilla</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This multicentre, prospective and randomized study aims(1:1) to compare the rate of
      recurrence, metastasis and survival according to the levels of intraoperative circulating
      tumor cells (CTCs) during cephalic duodenopancreatectomy in patients with pancreatic and
      periampullary tumors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cephalic duodenopancreatectomy is the technique indicated for patients with pancreatic head
      carcinoma and periampullar tumors.

      There are different technical variants, it is not standardized what is the best option in
      relation to local recurrence, metastasis and survival.

      In the study, patients will be randomized into two study groups with pancreatic and
      periampullary tumors undergoing cephalic pancreatectomy (NT) vs initial approach by superior
      mesenteric artery (SMA).

      The measurement of circulating tumor cells (CTCs) allows to assess the degree of cellular
      dissemination due to surgical manipulation.CTCs will be evaluated during surgery (nº CTCs /
      mL blood). To do this, a maximum of 4 blood samples from the portal vein will be performed,
      in each study group according to the following scheme:

        -  NT group: basal (at the beginning of surgery), portal vein pancreatic detachment,
           postresection (NT2) and before closure (NT3).

        -  SMA group: basal (at the beginning of surgery), after Kocher maneuver and SMA
           dissection, postresection, before closure.

      Subsequently, the quantified levels of CTCs will be correlated with the occurrence of local
      tumor recurrence, metastasis development and patient patient survival.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 15, 2017</start_date>
  <completion_date type="Anticipated">December 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 15, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Prospective, randomized (1:1) to 2 study groups according to duodenopancreatectomy surgical approach: &quot;No-Touch group&quot; (NT) or &quot;Artery First group&quot; (SMA) in patients with pancreatic and periampullary tumors, to evaluated circulating tumor cells (CTCs) levels during the surgery.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Circulating tumor cells (CTC´s)</measure>
    <time_frame>During the surgery: at the beginning of surgery, immediately after disconnecting the pancreas from the portal vein, just at the moment the pancreatic resection ends and before the skin closed</time_frame>
    <description>Change in the concentration of circulating tumor cells (CTCs) levels (nº CTCs/ mL blood) during the surgery, 4 blood samples will be taken from the portal vein</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Local tumor recurrence</measure>
    <time_frame>From the day of surgery to 3 years of follow-up</time_frame>
    <description>Presence (YES or NO) compatible images of local tumor recurrence Valid imaging tests of presence or absence can be checked by: computerized tomography (CT) or magnetic resonance (NMR)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Metastasis</measure>
    <time_frame>From the day of surgery to 3 years of follow-up</time_frame>
    <description>Presence (YES or NO) compatible images of metastasis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient survival</measure>
    <time_frame>From the day of surgery to 3 years of follow-up</time_frame>
    <description>Death (YES OR NO): number of patients dying during study</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Morbidity</measure>
    <time_frame>From the day of surgery up to 6 weeks of follow-up</time_frame>
    <description>The complications evaluation and their severity will be based on the classification of Dindo-Clavien and the definitions of the International Study Group of Pancreatic Surgery (ISGPS).
Pancreatic fistula: Presence (yes or no) and degree (A, B, C)
Delayed gastric emptying: Presence (yes or no) and degree (A, B, C)
Hemorrhage: Presence (yes or no) and degree (A, B, C)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">62</enrollment>
  <condition>Pancreatic Tumor</condition>
  <condition>Periampullary Carcinoma Resectable</condition>
  <condition>Circulating Tumor Cells</condition>
  <condition>Metastasis</condition>
  <arm_group>
    <arm_group_label>No Touch (NT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pancreatic and Periampullary Tumors resection by no-touch technique</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Superior Mesenteric Artery First (SMA)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pancreatic and Periampullary Tumors resection by superior Mesenteric Artery First technique</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>No Touch (NT)</intervention_name>
    <description>Tumor resection by No-touch technique: dissection of hepatic hilum, dissection of superior mesenteric vein (SMV) in caudal aspect of pancreas, section of antrum, pancreatic neck section. Section-ligation of veins of duodenopancreatectomy part of SMV and portal. Then Kocher-uncrossing maneuver of the jejunal loop and final section of the retro-portal (back of the portal vein) blade.</description>
    <arm_group_label>No Touch (NT)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Superior Mesenteric Artery First (SMA)</intervention_name>
    <description>Tumor resection by SMA technique: Kocher maneuver extends to the left renal vein (LRV). Dissection above the LRV of the SMA (refer to vessel-loop). Then, SMA will be identified on the caudal side of the pancreas (mesenterial root) and progressive dissection until its origin in the aorta artery (previously referenced with vessel loop).</description>
    <arm_group_label>Superior Mesenteric Artery First (SMA)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1. Patients older than 18 years, with adenocarcinomas of the pancreas and potentially
        resectable periampullary tumors by cephalic duodenopancreatectomy or total
        duodenopancreatectomy indicated intraoperatively for technical reasons, who voluntarily
        agree to participate in the study and sign informed consent

        Exclusion Criteria:

          1. Patients in whom liver metastases or peritoneal carcinomatosis are detected during
             surgery.

          2. Patients with neuroendocrine pancreatic tumors or cystic tumors.

          3. Patients in whom tumor resection is not finally achieved because it shows
             intraoperatively that the tumor is locally advanced and unresectable.

          4. Patients with macroscopic residual tumor (R2).

          5. High-risk patients with severe pathology (ASA IV) according to the American
             Association of Anesthesiologists.

          6. Patients receiving neoadjuvant therapy

          7. Patients in whom the intraoperative pathological anatomy indicates borders of
             pancreatic resection affected
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francisco Javier Padillo Ruiz, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospitales Universitarios Virgen del Rocío</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clara Rosso Fernández, PhD</last_name>
    <phone>+34955013414</phone>
    <email>claram.rosso.sspa@juntadeanadalucia.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lydia Barrera Pulido, PhD</last_name>
    <phone>+34955014236</phone>
    <email>lydia.barrera.exts@juntadeandalucia.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocío</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Javier Padillo, MD.PhD</last_name>
      <phone>34955013414</phone>
    </contact>
    <contact_backup>
      <last_name>Lydia Barrera, Phd</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Matsuno S, Egawa S, Fukuyama S, Motoi F, Sunamura M, Isaji S, Imaizumi T, Okada S, Kato H, Suda K, Nakao A, Hiraoka T, Hosotani R, Takeda K. Pancreatic Cancer Registry in Japan: 20 years of experience. Pancreas. 2004 Apr;28(3):219-30.</citation>
    <PMID>15084961</PMID>
  </reference>
  <reference>
    <citation>Kutomi G, Mizuguchi T, Satomi F, Maeda H, Shima H, Kimura Y, Hirata K. Current status of the prognostic molecular biomarkers in breast cancer: A systematic review. Oncol Lett. 2017 Mar;13(3):1491-1498. doi: 10.3892/ol.2017.5609. Epub 2017 Jan 17.</citation>
    <PMID>28454281</PMID>
  </reference>
  <reference>
    <citation>Jamieson NB, Foulis AK, Oien KA, Going JJ, Glen P, Dickson EJ, Imrie CW, McKay CJ, Carter R. Positive mobilization margins alone do not influence survival following pancreatico-duodenectomy for pancreatic ductal adenocarcinoma. Ann Surg. 2010 Jun;251(6):1003-10. doi: 10.1097/SLA.0b013e3181d77369.</citation>
    <PMID>20485150</PMID>
  </reference>
  <reference>
    <citation>Alamo JM, Marín LM, Suarez G, Bernal C, Serrano J, Barrera L, Gómez MA, Muntané J, Padillo FJ. Improving outcomes in pancreatic cancer: key points in perioperative management. World J Gastroenterol. 2014 Oct 21;20(39):14237-45. doi: 10.3748/wjg.v20.i39.14237. Review.</citation>
    <PMID>25339810</PMID>
  </reference>
  <reference>
    <citation>Sabater L, Calvete J, Aparisi L, Cánovas R, Muñoz E, Añón R, Roselló S, Rodríguez E, Camps B, Alfonso R, Sala C, Sastre J, Cervantes A, Lledó S. [Pancreatic and periampullary tumors: morbidity, mortality, functional results and long-term survival]. Cir Esp. 2009 Sep;86(3):159-66. doi: 10.1016/j.ciresp.2009.03.014. Epub 2009 Jul 18. Spanish.</citation>
    <PMID>19616203</PMID>
  </reference>
  <reference>
    <citation>Verbeke CS, Menon KV. Redefining resection margin status in pancreatic cancer. HPB (Oxford). 2009 Jun;11(4):282-9. doi: 10.1111/j.1477-2574.2009.00055.x.</citation>
    <PMID>19718354</PMID>
  </reference>
  <reference>
    <citation>Earl J, Garcia-Nieto S, Martinez-Avila JC, Montans J, Sanjuanbenito A, Rodríguez-Garrote M, Lisa E, Mendía E, Lobo E, Malats N, Carrato A, Guillen-Ponce C. Circulating tumor cells (Ctc) and kras mutant circulating free Dna (cfdna) detection in peripheral blood as biomarkers in patients diagnosed with exocrine pancreatic cancer. BMC Cancer. 2015 Oct 24;15:797. doi: 10.1186/s12885-015-1779-7.</citation>
    <PMID>26498594</PMID>
  </reference>
  <reference>
    <citation>Connor AA, McNamara K, Al-Sukhni E, Diskin J, Chan D, Ash C, Lowes LE, Allan AL, Zogopoulos G, Moulton CA, Gallinger S. Central, But Not Peripheral, Circulating Tumor Cells are Prognostic in Patients Undergoing Resection of Colorectal Cancer Liver Metastases. Ann Surg Oncol. 2016 Jul;23(7):2168-75. doi: 10.1245/s10434-015-5038-6. Epub 2015 Dec 29.</citation>
    <PMID>26714949</PMID>
  </reference>
  <reference>
    <citation>Poruk KE, Valero V 3rd, Saunders T, Blackford AL, Griffin JF, Poling J, Hruban RH, Anders RA, Herman J, Zheng L, Rasheed ZA, Laheru DA, Ahuja N, Weiss MJ, Cameron JL, Goggins M, Iacobuzio-Donahue CA, Wood LD, Wolfgang CL. Circulating Tumor Cell Phenotype Predicts Recurrence and Survival in Pancreatic Adenocarcinoma. Ann Surg. 2016 Dec;264(6):1073-1081.</citation>
    <PMID>26756760</PMID>
  </reference>
  <reference>
    <citation>BARNES JP. Physiologic resection of the right colon. Surg Gynecol Obstet. 1952 Jun;94(6):722-6.</citation>
    <PMID>14931182</PMID>
  </reference>
  <reference>
    <citation>Hirota M, Kanemitsu K, Takamori H, Chikamoto A, Tanaka H, Sugita H, Sand J, Nordback I, Baba H. Pancreatoduodenectomy using a no-touch isolation technique. Am J Surg. 2010 May;199(5):e65-8. doi: 10.1016/j.amjsurg.2008.06.035. Epub 2008 Dec 18.</citation>
    <PMID>19095210</PMID>
  </reference>
  <reference>
    <citation>Hirota M, Ogawa M. No-touch pancreatectomy for invasive ductal carcinoma of the pancreas. JOP. 2014 May 27;15(3):243-9. doi: 10.6092/1590-8577/2502.</citation>
    <PMID>24865535</PMID>
  </reference>
  <reference>
    <citation>Kobayashi S, Asano T, Ochiai T. A proposal of no-touch isolation technique in pancreatoduodenectomy for periampullary carcinomas. Hepatogastroenterology. 2001 Mar-Apr;48(38):372-4.</citation>
    <PMID>11379311</PMID>
  </reference>
  <reference>
    <citation>Gall TM, Jacob J, Frampton AE, Krell J, Kyriakides C, Castellano L, Stebbing J, Jiao LR. Reduced dissemination of circulating tumor cells with no-touch isolation surgical technique in patients with pancreatic cancer. JAMA Surg. 2014 May;149(5):482-5.</citation>
    <PMID>24599353</PMID>
  </reference>
  <reference>
    <citation>Pessaux P, Marzano E, Rosso E. A plea for the artery-first dissection during pancreaticoduodenectomy. J Am Coll Surg. 2010 Jul;211(1):142-3. doi: 10.1016/j.jamcollsurg.2010.03.026.</citation>
    <PMID>20610264</PMID>
  </reference>
  <reference>
    <citation>Weitz J, Rahbari N, Koch M, Büchler MW. The &quot;artery first&quot; approach for resection of pancreatic head cancer. J Am Coll Surg. 2010 Feb;210(2):e1-4. doi: 10.1016/j.jamcollsurg.2009.10.019. Epub 2009 Dec 3.</citation>
    <PMID>20113929</PMID>
  </reference>
  <reference>
    <citation>Sanjay P, Takaori K, Govil S, Shrikhande SV, Windsor JA. 'Artery-first' approaches to pancreatoduodenectomy. Br J Surg. 2012 Aug;99(8):1027-35. doi: 10.1002/bjs.8763. Epub 2012 May 9. Review.</citation>
    <PMID>22569924</PMID>
  </reference>
  <reference>
    <citation>Kuroki T, Eguchi S. No-touch isolation techniques for pancreatic cancer. Surg Today. 2017 Jan;47(1):8-13. Epub 2016 Mar 1. Review.</citation>
    <PMID>26931548</PMID>
  </reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 16, 2017</study_first_submitted>
  <study_first_submitted_qc>November 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 14, 2017</study_first_posted>
  <last_update_submitted>May 8, 2018</last_update_submitted>
  <last_update_submitted_qc>May 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplastic Cells, Circulating</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Yes. Anonymized data for individual participant data (IPD) is planned to be shared with all participants within 6 months of data completion</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

